{"id":"W2790385254","doi":"10.1158/1538-7445.sabcs17-ot3-05-02","title":"Abstract OT3-05-02: BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of <i>PIK3CA</i> mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2<i>–</i>) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibitor therapy","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Letrozole; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Cancer; Metastatic breast cancer; Breast cancer; Estrogen receptor; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005227103,0.000934158,0.001692152,0.0005461192,0.0005363459,0.00007323373,0.0004316972,0.0002380548,0.001120691],"category_scores_gemma":[0.00008343095,0.0006348911,0.0002773247,0.001047686,0.001689901,0.0005561458,0.00008552951,0.0005908509,0.00001068701],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001929729,"about_ca_system_score_gemma":0.001401534,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002308835,"about_ca_topic_score_gemma":0.001135822,"domain_scores_codex":[0.9934455,0.0003757075,0.001231278,0.001533726,0.001926903,0.001486901],"domain_scores_gemma":[0.9940882,0.0006088927,0.0007841623,0.0009683499,0.002955083,0.0005953126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1815691,0.01063111,0.002982782,0.0003049499,0.0015186,0.0001403572,0.009979703,0.000021179,0.5919288,0.000007756569,0.0001551249,0.2007605],"study_design_scores_gemma":[0.05790029,0.06093958,0.02910818,0.001832875,0.00018084,0.00003699449,0.004884804,0.000008860823,0.843198,0.00003179938,0.001163398,0.0007143746],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821851,0.003093254,0.00007354366,0.0009463484,0.0002761592,0.008615672,0.00463662,0.00009522794,0.00007812502],"genre_scores_gemma":[0.9891679,0.001433527,0.001131591,0.0001425355,0.001427879,0.006025395,0.00007954911,0.0002736092,0.0003180362],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2512691,"threshold_uncertainty_score":0.9997924,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06258979464817743,"score_gpt":0.4222820193877104,"score_spread":0.359692224739533,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}